First-line therapy based on kinase inhibitors and antibodies prevents resistance in egfr-mutated lung cancer.

Authors
Publication date
1 January 2022
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Archivio istituzionale della ricerca - Alma Mater Studiorum Università di Bologna

    redirect
    oaioai:cris.unibo.it:11585/884609
    Last time updated on 11/07/2022